{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:01:44Z","timestamp":1791396104306,"version":"4.3.3"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment of tuberculosis infection (TBI) is a key pillar of the World Health Organization End TB Strategy. Two short-course rifamycin-based regimens\u20143 months of weekly isoniazid plus rifapentine (3HP) and 4 months of daily rifampicin (4RIF)\u2014are widely recommended; however, they have not previously been directly compared in a randomized controlled trial. We compared treatment completion between 3HP and 4RIF among individuals with TBI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter, open-label, parallel-group randomized controlled trial across 7 tuberculosis clinics in Sydney, Australia, between July 2019 and June 2024. Participants of any age with TBI were randomized 1:1, stratified by site, to receive either weekly 3HP or daily 4RIF. All doses were self-administered. Participants in the 3HP group received weekly Short Message Service (SMS) adherence reminders; both groups received standard clinic follow-up. The primary outcome was treatment completion, defined as ingestion of \u226590% of prescribed doses. Analyses were conducted on an intention-to-treat basis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 210 participants were enrolled (106 assigned to 3HP and 104 to 4RIF). Treatment completion was significantly higher in the 3HP group (84.9%) than in the 4RIF group (65.4%; relative risk, 1.30 [95% confidence interval, 1.22\u20131.38]; P &amp;lt; .001). Adverse events of any grade occurred in 24.5% of participants receiving 3HP and 20.2% receiving 4RIF. No treatment-related deaths were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Weekly 3HP supported by SMS reminders achieved significantly higher treatment completion than daily 4RIF, with similar safety. These findings support broader implementation of 3HP to optimize adherence and outcomes in TBI treatment programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>Australian New Zealand Clinical Trials Registry (ACTRN12618001672246).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag306","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:44:09Z","timestamp":1778067849000},"page":"e539-e547","source":"Crossref","is-referenced-by-count":1,"title":["Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial"],"prefix":"10.1093","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4880-9082","authenticated-orcid":false,"given":"Vicky W L","family":"Chang","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney , Sydney, New South Wales ,","place":["Australia"]},{"name":"St George Hospital , Kogarah, Sydney, New South Wales ,","place":["Australia"]},{"name":"Westmead Hospital , Westmead, Sydney, New South Wales ,","place":["Australia"]},{"name":"University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7882-1319","authenticated-orcid":false,"given":"Qingbin","family":"Li","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Barnes","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney , Sydney, New South Wales ,","place":["Australia"]},{"name":"Royal Prince Alfred Hospital , Sydney, Camperdown, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3192-0726","authenticated-orcid":false,"given":"Anthony L","family":"Byrne","sequence":"additional","affiliation":[{"name":"University of New South Wales , Sydney, New South Wales ,","place":["Australia"]},{"name":"St Vincent Hospital , Darlinghurst, Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-4691","authenticated-orcid":false,"given":"Jin-Gun","family":"Cho","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney , Sydney, New South Wales ,","place":["Australia"]},{"name":"Westmead Hospital , Westmead, Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8763-4298","authenticated-orcid":false,"given":"SooWei","family":"Foo","sequence":"additional","affiliation":[{"name":"Concord Repatriation General Hospital , Concord, Sydney, New South Wales ,","place":["Australia"]},{"name":"Macarthur Clinical School, Western Sydney University , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel","family":"Goldberg","sequence":"additional","affiliation":[{"name":"St George Hospital , Kogarah, Sydney, New South Wales ,","place":["Australia"]},{"name":"University of New South Wales , Sydney, New South Wales ,","place":["Australia"]},{"name":"Prince of Wales Hospital , Randwick, Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2591-0284","authenticated-orcid":false,"given":"Timothy","family":"Gray","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney , Sydney, New South Wales ,","place":["Australia"]},{"name":"Concord Repatriation General Hospital , Concord, Sydney, New South Wales ,","place":["Australia"]},{"name":"Canterbury Hospital , Campsie, Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-5598","authenticated-orcid":false,"given":"Zinta","family":"Harrington","sequence":"additional","affiliation":[{"name":"University of New South Wales , Sydney, New South Wales ,","place":["Australia"]},{"name":"Liverpool Hospital , Liverpool, Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4244-9125","authenticated-orcid":false,"given":"Lydia M","family":"Rofail","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney , Sydney, New South Wales ,","place":["Australia"]},{"name":"Concord Repatriation General Hospital , Concord, Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Ulbricht","sequence":"additional","affiliation":[{"name":"Westmead Hospital , Westmead, Sydney, New South Wales ,","place":["Australia"]},{"name":"New South Wales Tuberculosis Program, NSW Health , St Leonards New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J","family":"Fox","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney , Sydney, New South Wales ,","place":["Australia"]},{"name":"Royal Prince Alfred Hospital , Sydney, Camperdown, New South Wales ,","place":["Australia"]},{"name":"NHMRC Clinical Trials Centre, Faculty of Medicine and Health, The University of Sydney , Camperdown, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2026100713434772800_ciag306-B1","volume-title":"Global tuberculosis report 2023","author":"World Health Organization","year":"2023"},{"key":"2026100713434772800_ciag306-B2","volume-title":"Global tuberculosis report 2024","author":"World Health Organization","year":"2024"},{"key":"2026100713434772800_ciag306-B3","first-page":"CD000171","article-title":"Treatment of latent tuberculosis infection in HIV infected persons","volume":"2010","author":"Akolo","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2026100713434772800_ciag306-B4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1164\/ajrccm.162.5.2004154","article-title":"Incidence of tuberculosis among a cohort of tuberculin-positive refugees in Australia: reappraising the estimates of risk","volume":"162","author":"Marks","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100713434772800_ciag306-B5","year":"2019"},{"key":"2026100713434772800_ciag306-B6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M14-1019","article-title":"Treatment of latent tuberculosis infection: a network meta-analysis","volume":"161","author":"Stagg","year":"2014","journal-title":"Ann Intern Med"},{"key":"2026100713434772800_ciag306-B7","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","author":"World Health Organization","year":"2018"},{"key":"2026100713434772800_ciag306-B8","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2026100713434772800_ciag306-B9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N Engl J Med"},{"key":"2026100713434772800_ciag306-B10","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"key":"2026100713434772800_ciag306-B11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomised clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatric"},{"key":"2026100713434772800_ciag306-B12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"2026100713434772800_ciag306-B13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1714284","article-title":"Safety and side effects of rifampin versus isoniazid in children","volume":"379","author":"Diallo","year":"2018","journal-title":"N Engl J Med"},{"key":"2026100713434772800_ciag306-B14","author":"National Cancer Institute"},{"key":"2026100713434772800_ciag306-B15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT Tuberculosis study","volume":"61","author":"Sterling","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026100713434772800_ciag306-B16","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(23)00096-6","article-title":"Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis","volume":"11","author":"Winters","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026100713434772800_ciag306-B17","author":"Stop TB Partnership\/Global Drug Facility"},{"key":"2026100713434772800_ciag306-B18","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis","volume":"16","author":"Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026100713434772800_ciag306-B19","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/imj.13601","article-title":"SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication","volume":"47","author":"Denholm","year":"2017","journal-title":"Internal Med J"},{"key":"2026100713434772800_ciag306-B20","volume-title":"WHO encourages manufacturers to develop quality assured formulations of the game-changing drug rifapentine","author":"World Health Organization","year":"2021"},{"key":"2026100713434772800_ciag306-B21","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag306\/68290404\/ciag306.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/3\/e539\/68290404\/ciag306.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/3\/e539\/68290404\/ciag306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:43:57Z","timestamp":1791395037000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/83\/3\/e539\/8678684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,15]]},"published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag306","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,15]]},"published":{"date-parts":[[2026,5,15]]}}}